Literature DB >> 18199536

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

Hua Yang1, William Kong, Lili He, Jian-Jun Zhao, Joshua D O'Donnell, Jiawang Wang, Robert M Wenham, Domenico Coppola, Patricia A Kruk, Santo V Nicosia, Jin Q Cheng.   

Abstract

MicroRNAs (miRNA) represent a novel class of genes that function as negative regulators of gene expression. Recently, miRNAs have been implicated in several cancers. However, aberrant miRNA expression and its clinicopathologic significance in human ovarian cancer have not been well documented. Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster. Further, we show the frequent deregulation of miR-214, miR-199a*, miR-200a, and miR-100 in ovarian cancers. Significantly, miR-214 induces cell survival and cisplatin resistance through targeting the 3'-untranslated region (UTR) of the PTEN, which leads to down-regulation of PTEN protein and activation of Akt pathway. Inhibition of Akt using Akt inhibitor, API-2/triciribine, or introduction of PTEN cDNA lacking 3'-UTR largely abrogates miR-214-induced cell survival. These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199536     DOI: 10.1158/0008-5472.CAN-07-2488

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  487 in total

1.  MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Authors:  Xiao He; Xia Xiao; Lin Dong; Nengbin Wan; Zhengyu Zhou; Hongwu Deng; Xiefu Zhang
Journal:  Tumour Biol       Date:  2014-11-15

2.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

Review 3.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

4.  RAB8 enhances TMEM205-mediated cisplatin resistance.

Authors:  Ding-Wu Shen; Michael M Gottesman
Journal:  Pharm Res       Date:  2011-10-04       Impact factor: 4.200

Review 5.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

6.  Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation.

Authors:  Bing Liu; Lin Liu; Anna Tsykin; Gregory J Goodall; Jeffrey E Green; Min Zhu; Chang Hee Kim; Jiuyong Li
Journal:  Bioinformatics       Date:  2010-10-17       Impact factor: 6.937

7.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

8.  Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Authors:  Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner
Journal:  Mol Cancer Res       Date:  2019-01-03       Impact factor: 5.852

9.  MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1.

Authors:  Jian-Mei Wang; Bao-Hui Ju; Cai-Jun Pan; Yan Gu; Meng-Qi Li; Li Sun; Yan-Ying Xu; Li-Rong Yin
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

10.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Authors:  Nuo Yang; Sippy Kaur; Stefano Volinia; Joel Greshock; Heini Lassus; Kosei Hasegawa; Shun Liang; Arto Leminen; Shan Deng; Lori Smith; Cameron N Johnstone; Xian-Ming Chen; Chang-Gong Liu; Qihong Huang; Dionyssios Katsaros; George Adrian Calin; Barbara L Weber; Ralf Bützow; Carlo M Croce; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.